CBRE vs EDIT · P/E 43, rev $35.77B vs rev $32.3M
CBRE Group Inc Class A (CBRE) versus Editas Medicine Inc (EDIT) — a side-by-side from cached financials, not a winner call.
CBRE Group Inc Class A (CBRE) is a real estate services company listed on US.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Latest reported CBRE revenue for 2024-12-31 was $35.77B. Net income was $1.04B. Revenue was up 12.0% from 2023-12-31 to 2024-12-31. CBRE currently screens at market cap $41.66B and trailing P/E 42.7.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
CBRE currently screens at market cap $41.66B and trailing P/E 42.7. EDIT currently screens at market cap $375.2M.
Not investment advice. Open the CBRE and EDIT stock pages for the full models.
Not investment advice.